Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

  • Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small molecules
  • Adcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field

Copenhagen, Denmark, May 3, 2022 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, today announces the appointment of Dominik Mumberg, PhD, as Chief Scientific Officer (CSO).

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH